ArticlePsychopharmacology2026
Sotagliflozin pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities and modulates the gut microbiota-immune-brain axis.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
rationaleInflammation-driven depression is increasingly recognized as a major therapeutic target, yet effective pharmacological strategies remain limited. Sotagliflozin (SOTA), a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), has demonstrated anti-inflammatory and metabolic benefits, but its neuropsychiatric effects remain unclear.
objectivesThis study investigated whether SOTA pretreatment attenuates acute lipopolysaccharide (LPS)-induced depression-like behavioral abnormalities and modulates the gut microbiota-immune-brain axis.
methodsMale mice received SOTA for 7 days before LPS injection. Behavioral outcomes were assessed using the open field test and forced swimming test. Systemic inflammation, hippocampal synaptic protein expression, and gut microbiota composition were evaluated using ELISA, Western blotting, and 16S rRNA sequencing, respectively.
resultsSOTA pretreatment attenuated the LPS-induced reduction in open field center time and increase in forced swimming immobility time. SOTA also reduced LPS-induced splenomegaly and serum IL-6 and TNF-α levels. Western blotting showed that SOTA blunted the LPS-induced reductions in hippocampal GluA1 and PSD-95 expression. 16S rRNA sequencing demonstrated that SOTA partially normalized LPS-associated gut dysbiosis and modulated the relative abundance of genera including Enterococcus, Coriobacteriaceae UCG-002, and Parvibacter. Exploratory correlation and functional prediction analyses linked these taxa to behavioral and inflammatory markers and implicated predicted steroid and triterpenoid biosynthesis pathways.
conclusionsSOTA pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities in association with reduced systemic inflammation, blunted synaptic protein loss, and altered gut microbiota profiles. Dual SGLT1/2 inhibition warrants further investigation in inflammation-associated mood disorders.
Indexed as
Identifiers
42412140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.